Innoviva's shift to specialty therapeutics is backed by strong financials and a robust pipeline. Read why INVA stock presents ...

Linezolid Nosocomial pneumonia, cSSSI Oral ... MRSA has become a global health problem. New resistance types, such as vancomycin-resistant S. aureus, have been recently developed. Novel ...

Quoin Pharmaceuticals (QNRX) announced the launch of the first episode in its “Living with Netherton” video series dedicated to giving voice to ...

Global Premiere Set for Rare Disease Day, Feb. 28, 2025ASHBURN, Va., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals ...

including MRSA, and B. anthracis, a pathogen considered a bioterrorism threat. Acurx’s ibezapolstat, a minimally absorbed oral antibiotic, is now Phase 3-ready for the treatment and prevention of C.

Metaba, LLC ( and MAX BioPharma, Inc. ( are pleased to announce significant progress in their collaboration to develop oxysterol-based drug candidates targeting bacterial pathogens. This pioneering ...

He added: "Other compounds in our program are systemically absorbed for potential oral ... antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, ...

Acurx Pharmaceuticals’ DNA Polymerase IIIC Inhibitors receives Japanese patent: Staten Island, New York Thursday, February 20, 2025, 18:00 Hrs [IST] Acurx Pharmaceuticals, Inc., ...

Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin ...

Scalded skin syndrome from staph bacteria generally covers the entire body. Infants are particularly susceptible. Learn which ...